In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva Pharmaceutical ...

In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Shares of NYSE TEVA opened at $17.81 on Thursday. Teva Pharmaceutical Industries has a 12 month low of $11.62 and a 12 month high of $22.80. The company has a market cap of $20.17 billion, a P/E ...

Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus (NYSE:TEVA). And retail traders should know. We noticed this today when the trades showed up on ...